Transfusion in hemoglobinopathies and red blood cell alloimmunization: data from Sicily, Sardinia and Malta
- 1 March 2024
- journal article
- research article
- Vol. 22 (2) , 111-121
Abstract
Background - Hemoglobinopathies are a group of diseases that include those due to globin gene mutations, such as thalassemia major (TM) and thalassemia intermedia (TI) or due to alteration of hemoglobin structure such as sickle cell disease (SCD), as well as a combination of these conditions such as thalasso-drepanocytosis (TD). They constitute the most frequent hereditary anemias requiring blood transfusion. Materials and methods - In April 2022, a questionnaire was sent to the Transfusion Services (TS) of Sicily, Sardinia and the Maltese National Blood Transfusion (MNBT) service. The questionnaire was divided into a generic part including the number of patients followed and the type of hemoglobinopathy, and a section relating to transfusion therapy, including the number of units transfused, whether red blood cells (RBC) were washed and, finally, a section relating to the presence or absence of alloantibodies and their identification. Results - Data was retrieved for 2,574 patients: 68.6% TM, 15.4% TI, 10.3% TD, 4.1% SCD, and 1.6% other hemoglobinopathies (OHA). The number of RBC units transfused was 76,974, equivalent to 24.5% of all the RBCU transfused from the total number of patients followed. The number of washed RBCU was 21.1% of all the units used; 337 patients (37%) were diagnosed with alloantibodies, the majority of which were patients with SCD (20.6%). Of the 485 alloantibodies found, 90.3% were identified. The antibodies found most frequently were related to the Kell system (41.7%) followed by antibodies to the Rhesus system (37.9%); 29.7% of patients had more than one antibody. Discussion - From our study, certain indications can be formulated: 1) complete the National Registry for patients with hemoglobinopathies; 2) create a Registry of alloimmunized patients to ensure transfusion therapy is as safe as possible, considering antibody evanescence; and 3) increase the recruitment of blood donors of diverse ethnicities.Keywords
This publication has 29 references indexed in Scilit:
- Mapping anticipated advantages and disadvantages of implementation of extensive donor genotyping: A focus group approachTransfusion Medicine, 2022
- An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centresBritish Journal of Haematology, 2021
- Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell diseaseBritish Journal of Haematology, 2021
- Position paper on International Collaboration for Transfusion Medicine (ICTM) Guideline ‘Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline’British Journal of Haematology, 2020
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special IssueJournal of Clinical Apheresis, 2019
- Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspectsBritish Journal of Haematology, 2016
- The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?British Journal of Haematology, 2016
- Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratoriesTransfusion Medicine, 2012
- Alloimmunization to red cells in thalassemics: Emerging problem and future strategiesTransfusion and Apheresis Science, 2011
- Red‐blood‐cell alloimmunization and number of red‐blood‐cell transfusionsVox Sanguinis, 2011